Stock Performance and Market Context
On 20 May 2026, Integrated Proteins Ltd opened and traded steadily at Rs.131.90, registering a daily gain of 1.97%. This outpaced the Sensex, which declined by 0.42% on the same day, and notably outperformed the solvent extraction sector, which fell by 4.25%. The stock’s performance over recent periods has been remarkable, with a 13-day consecutive gain resulting in a cumulative return of 26.64% during this stretch.
Over longer time horizons, the stock’s returns have been extraordinary. Year-to-date, Integrated Proteins Ltd has surged by 283.43%, vastly outperforming the Sensex’s decline of 12.13%. Over one year, the stock delivered a 199.09% return compared to the Sensex’s negative 7.76%. The three-year performance is even more striking, with a gain of 1,095.83% against the Sensex’s 21.31%. Extending further back, the ten-year return stands at an impressive 6,063.55%, dwarfing the Sensex’s 195.97% gain over the same period.
Technical Indicators Confirm Bullish Momentum
The technical outlook for Integrated Proteins Ltd remains strongly bullish. The current trend, which shifted from sideways to bullish on 27 March 2026 at a price of Rs.71.33, has been supported by multiple indicators. Weekly and monthly MACD readings are bullish, as are Bollinger Bands and moving averages across short and long terms. The stock is trading above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, signalling sustained upward momentum.
Key support and resistance levels further illustrate the stock’s strength. The immediate support is anchored at the 52-week low of Rs.20.71, while the previous resistance at Rs.110.37 (20-day moving average) has been decisively surpassed. The stock’s new all-time high at Rs.131.90 now represents a far resistance level, underscoring the significant price appreciation achieved.
Valuation Metrics Reflect Elevated Market Expectations
Valuation multiples for Integrated Proteins Ltd as of 20 May 2026 indicate a premium pricing reflective of the stock’s rapid ascent. The price-to-earnings (P/E) ratio stands at an elevated 734 times trailing twelve months earnings, while the price-to-book value (P/BV) ratio is 11.89 times. Enterprise value multiples are also high, with EV/EBITDA and EV/EBIT both at 242.06 times, and EV/Sales at 9.42 times. These figures suggest that the market is pricing in significant growth and profitability expectations, despite the company’s current earnings profile.
Dividend metrics remain unavailable, with no dividend yield or payout reported, consistent with the company’s reinvestment focus and growth phase.
Quality Assessment Highlights Growth Amid Financial Constraints
Integrated Proteins Ltd’s quality assessment indicates a below-average overall quality grade, reflecting certain financial challenges alongside strong growth. The company has demonstrated a healthy five-year sales compound annual growth rate (CAGR) of 92.87%, signalling robust top-line expansion. However, earnings before interest and tax (EBIT) growth over five years is more modest at 7.26%, and profitability ratios such as average return on capital employed (ROCE) and return on equity (ROE) remain weak at -5.14% and 1.51% respectively.
Capital structure appears conservative, with negligible debt levels (average debt to EBITDA of 0.46 and net debt to equity near zero) and no promoter share pledging. The company’s tax ratio stands at 21.43%, and dividend payout is nil, consistent with reinvestment in growth initiatives. Institutional holdings are minimal, reflecting the micro-cap status and niche market positioning.
Delivery Volumes and Trading Activity
Recent delivery volumes have shown a marked increase, with a 92.09% rise over the past month and a 34.37% increase on the day of the all-time high compared to the five-day average. This heightened trading activity underscores growing market participation and liquidity in the stock, supporting the sustained price appreciation.
Summary of Market and Technical Developments
Integrated Proteins Ltd’s journey to its all-time high of Rs.131.90 is characterised by consistent gains, strong technical signals, and significant outperformance relative to sector peers and the broader market. The stock’s upward momentum has been sustained over multiple time frames, supported by bullish technical indicators and increasing delivery volumes. While valuation multiples are elevated, reflecting high market expectations, the company’s impressive sales growth and solid balance sheet provide context for the premium pricing.
This milestone represents a noteworthy achievement for Integrated Proteins Ltd within the edible oil sector, highlighting its evolution from a modest base price of Rs.20.71 over the past year to a commanding market presence. The stock’s performance over the last decade, with returns exceeding 6,000%, further emphasises the scale of value creation realised by shareholders during this period.
